Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives $56.33 Consensus Target Price from Brokerages

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has been given a consensus recommendation of “Moderate Buy” by the eight analysts that are currently covering the stock, MarketBeat reports. Four equities research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $56.33.

Several research firms have issued reports on AGIO. Raymond James reiterated an “outperform” rating and set a $51.00 price objective on shares of Agios Pharmaceuticals in a research note on Thursday, October 10th. StockNews.com raised shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, November 9th. Royal Bank of Canada increased their price target on Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an “outperform” rating in a report on Tuesday. Cantor Fitzgerald restated an “overweight” rating on shares of Agios Pharmaceuticals in a research note on Friday, September 20th. Finally, Leerink Partnrs downgraded Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, September 27th.

Agios Pharmaceuticals Stock Performance

Shares of NASDAQ:AGIO opened at $38.97 on Wednesday. Agios Pharmaceuticals has a 1 year low of $20.96 and a 1 year high of $62.58. The stock has a 50-day simple moving average of $50.02 and a 200-day simple moving average of $46.64. The stock has a market capitalization of $2.22 billion, a P/E ratio of 3.43 and a beta of 0.80.

Insider Buying and Selling at Agios Pharmaceuticals

In related news, CFO Cecilia Jones sold 2,542 shares of the business’s stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $49.03, for a total value of $124,634.26. Following the transaction, the chief financial officer now owns 20,158 shares in the company, valued at approximately $988,346.74. The trade was a 11.20 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 4.93% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Agios Pharmaceuticals

Hedge funds have recently bought and sold shares of the business. Acadian Asset Management LLC purchased a new position in shares of Agios Pharmaceuticals during the 2nd quarter valued at approximately $37,000. Quest Partners LLC bought a new stake in shares of Agios Pharmaceuticals in the second quarter worth $40,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in Agios Pharmaceuticals by 21.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,058 shares of the biopharmaceutical company’s stock valued at $94,000 after acquiring an additional 363 shares in the last quarter. CWM LLC boosted its stake in Agios Pharmaceuticals by 554.7% during the 3rd quarter. CWM LLC now owns 2,167 shares of the biopharmaceutical company’s stock valued at $96,000 after acquiring an additional 1,836 shares during the last quarter. Finally, Quantbot Technologies LP bought a new position in Agios Pharmaceuticals during the 3rd quarter valued at $146,000.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.